Actuate Therapeutics (NASDAQ:ACTU) Given New $15.00 Price Target at HC Wainwright

Actuate Therapeutics (NASDAQ:ACTU) had its price target decreased by HC Wainwright from $20.00 to $15.00 in a research report report published on Monday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Several other analysts also recently commented on the company. Wall Street Zen upgraded Actuate Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, April 4th. Weiss Ratings restated a “sell (e+)” rating on shares of Actuate Therapeutics in a research note on Friday, March 27th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $18.67.

Actuate Therapeutics Price Performance

Shares of ACTU opened at $1.82 on Monday. The stock has a 50-day moving average of $3.16 and a 200-day moving average of $5.36. The company has a market cap of $43.15 million, a PE ratio of -1.73 and a beta of 0.85. Actuate Therapeutics has a one year low of $1.58 and a one year high of $11.99.

Actuate Therapeutics (NASDAQ:ACTU) last issued its earnings results on Thursday, March 26th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.06.

Hedge Funds Weigh In On Actuate Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Sfmg LLC lifted its position in Actuate Therapeutics by 17.6% in the 4th quarter. Sfmg LLC now owns 20,000 shares of the company’s stock valued at $122,000 after acquiring an additional 3,000 shares in the last quarter. Barclays PLC lifted its position in Actuate Therapeutics by 68.6% in the 4th quarter. Barclays PLC now owns 14,946 shares of the company’s stock valued at $91,000 after acquiring an additional 6,081 shares in the last quarter. State Street Corp lifted its position in Actuate Therapeutics by 12.8% in the 4th quarter. State Street Corp now owns 56,290 shares of the company’s stock valued at $344,000 after acquiring an additional 6,395 shares in the last quarter. ABS Direct Equity Fund LLC bought a new position in Actuate Therapeutics in the 4th quarter valued at about $40,000. Finally, Wells Fargo & Company MN lifted its position in Actuate Therapeutics by 48.8% in the 4th quarter. Wells Fargo & Company MN now owns 20,146 shares of the company’s stock valued at $123,000 after acquiring an additional 6,604 shares in the last quarter.

Actuate Therapeutics Company Profile

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.